CDMO Revenue Target: Rs 2,000 crore by FY30
Reaffirmed long-term CDMO revenue target with 10 molecules already secured contributing Rs 1,200 crore peak annual revenue; expects 20-60-100% ramp-up trajectory over 3 years for most molecules.
JUBLINGREA / guidance tracker
Keep management guidance in view.
Jubilant Ingrevia · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
Major CDMO Contract Starting Q4 FY26
$300 million (~$500 crore annual) 5-year exclusive agro innovator contract expected to begin supplies in January-March 2026, contributing significantly to FY27 revenues.
Nutrition Margin Recovery to 16-18%
Expects nutrition segment margins to recover from current 12-14% as high-value cosmetic/food/pharma grade mix increases to 60-70% utilization levels, targeting 18-24 month ramp-up.
FY26 Capex of Rs 600 Crore
Investments directed toward $300 million agro plant (Q4 commissioning), new MPP in Gajraula, Bharuch boiler, and debottlenecking existing capacity by 15-20%.
Q4 FY26 Expected to Be Better Than Q3
Management expects improved performance in Q4 driven by pricing recovery in specialty chemicals and nutrition, partial recovery in acetate portfolio, and commencement of large CDMO dispatch.
FY27 Pivotal Year for CDMO Growth
With new agro CDMO plant commissioning, multi-purpose Gajola facility construction underway, and 100+ pipeline opportunities, FY27 expected to see significant capacity utilization acceleration at ~50% utilized assets.
FY27 Capex of Rs 500 Crore Planned
Year-to-date capex of Rs 366 crore largely directed toward Bharuch CDMO/agro plant and Gajola multi-purpose facility; next fiscal year investment of approximately Rs 500 crore to be funded through internal accruals.
Specialty Chemicals Margin Aspiration Above 25%
Target to sustain EBITDA margins at minimum 25% in specialty chemicals through continued cost initiatives, improved product mix with higher fine chemicals/CDMO share, and pricing recovery.
FY27 EBITDA growth target of at least 20% YoY
Management maintained its target of achieving at least 20% year-on-year EBITDA growth for FY27, expecting sequential improvement starting from Q1 itself as multiple growth drivers converge.
Gajola niacin plant commencing production in Q4 FY27
Construction of the Gajola niacin plant is progressing well and will commence production in Q4 FY27, adding to the CDMO growth roadmap with further capacity for specialty chemicals.
FY27 capex of ₹400-500 crore
The company will continue investing behind growth with annual capex of ₹400-500 crore in FY27, with major investment going into the Gajola niacin plant which will be completed this year.
CDMO business growth to accelerate in FY27
The CDMO business, growing at 30-40% annually, is expected to accelerate further in FY27 with the large agro contract now in commercial execution phase and late-stage opportunities in the pipeline.